MA42440A - Anticorps qui se lient à la sortiline et inhibent la liaison de la progranuline - Google Patents

Anticorps qui se lient à la sortiline et inhibent la liaison de la progranuline

Info

Publication number
MA42440A
MA42440A MA042440A MA42440A MA42440A MA 42440 A MA42440 A MA 42440A MA 042440 A MA042440 A MA 042440A MA 42440 A MA42440 A MA 42440A MA 42440 A MA42440 A MA 42440A
Authority
MA
Morocco
Prior art keywords
sortiline
antibodies
bind
inhibit
progranulin binding
Prior art date
Application number
MA042440A
Other languages
English (en)
Inventor
Rønn Lars Christian Biilmann
Søren Christensen
Jong Rob De
Jan Egebjerg
Arnout Gerritsen
Ibrahim John Malik
Paul Parren
Jeffrey B Stavenhagen
Den Brink Edward Van
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA42440A publication Critical patent/MA42440A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA042440A 2015-07-13 2016-07-12 Anticorps qui se lient à la sortiline et inhibent la liaison de la progranuline MA42440A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1512215.3A GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods

Publications (1)

Publication Number Publication Date
MA42440A true MA42440A (fr) 2018-05-23

Family

ID=54013862

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042440A MA42440A (fr) 2015-07-13 2016-07-12 Anticorps qui se lient à la sortiline et inhibent la liaison de la progranuline

Country Status (31)

Country Link
US (5) US10428147B2 (fr)
EP (1) EP3322726A1 (fr)
JP (2) JP6979397B2 (fr)
KR (1) KR20180030045A (fr)
CN (3) CN114478774A (fr)
AR (1) AR105335A1 (fr)
AU (1) AU2016292980B2 (fr)
BR (1) BR112018000771A2 (fr)
CA (1) CA2989739A1 (fr)
CL (2) CL2018000092A1 (fr)
CO (1) CO2017012988A2 (fr)
CR (1) CR20180002A (fr)
DO (1) DOP2018000014A (fr)
EA (1) EA201890038A1 (fr)
EC (1) ECSP18002725A (fr)
GB (1) GB201512215D0 (fr)
HK (1) HK1254356A1 (fr)
IL (1) IL256503B (fr)
JO (1) JO3710B1 (fr)
MA (1) MA42440A (fr)
MX (1) MX2018000506A (fr)
NI (1) NI201800007A (fr)
PE (1) PE20181014A1 (fr)
PH (1) PH12018500100A1 (fr)
RU (1) RU2735639C2 (fr)
SV (1) SV2018005613A (fr)
TN (1) TN2017000534A1 (fr)
TW (1) TWI760305B (fr)
UA (1) UA125136C2 (fr)
WO (1) WO2017009327A1 (fr)
ZA (1) ZA201708613B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL254887B2 (en) * 2015-04-07 2023-11-01 Alector Llc Anti-sortilin antibodies and methods of using them
WO2016164608A1 (fr) 2015-04-07 2016-10-13 Alector Llc Procédés de recherche par criblage d'antagonistes de liaison à la sortiline
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
US11396546B2 (en) * 2018-07-13 2022-07-26 Alector Llc Anti-Sortilin antibodies and methods of use thereof
JP2023533458A (ja) * 2020-06-24 2023-08-03 プロシーナ バイオサイエンシーズ リミテッド ソルチリンを認識する抗体
WO2023247754A1 (fr) 2022-06-23 2023-12-28 Draupnir Bio Aps Molécules bifonctionnelles qui induisent sélectivement la dégradation de cibles extracellulaires dans des lysosomes
CN118496354A (zh) * 2023-02-15 2024-08-16 三优生物医药(上海)有限公司 包含共同轻链的抗体库、其制备方法及其用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE172879T1 (de) 1989-08-09 1998-11-15 Rhomed Inc Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
EP0593592B1 (fr) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Copolymere en masse segmentee a cristaux liquides thermotropiques
JP3801196B2 (ja) 1993-03-09 2006-07-26 ジェンザイム・コーポレイション 乳からの対象化合物の単離
CA2161351C (fr) 1993-04-26 2010-12-21 Nils Lonberg Animaux transgeniques, pouvant produire des anticorps heterologues
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
ATE276199T1 (de) 1999-02-03 2004-10-15 Biosante Pharmaceuticals Inc Methoden zur herstellung von therapeutische kalzium-phosphat partikeln
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
DE60037896D1 (de) 1999-07-29 2008-03-13 Medarex Inc Menschliche antikörper gegen her2/neu
US6984720B1 (en) 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
EP1916303B1 (fr) 2000-11-30 2013-02-27 Medarex, Inc. Acides nucléiques codant des séquences d'immunoglobulines humaines réarrangées obtenus de souris transgéniques chromosomales
CA2491864C (fr) 2001-07-12 2012-09-11 Jefferson Foote Anticorps super humanises
EP1589988A2 (fr) 2002-12-20 2005-11-02 Neuronicon ApS Modulation de l'activite de neurotrophines
CA2631184A1 (fr) 2005-11-28 2007-05-31 Genmab A/S Anticorps monovalents recombines et leurs procedes de production
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
EP3225251B1 (fr) 2006-12-21 2020-02-12 H. Lundbeck A/S Modulation de l'activité des proneurotrophines
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
WO2009132656A2 (fr) 2008-04-27 2009-11-05 H. Lundbeck A/S Mise au point de ligands spécifiques de la sortiline
WO2009154995A2 (fr) 2008-05-27 2009-12-23 Kyowa Hakko Kirin Co., Ltd. Anticorps du récepteur de l'interleukine 10 (il-10r) et méthodes d'utilisation
WO2010022175A1 (fr) 2008-08-19 2010-02-25 Yale University Identification de la sortiline en tant que récepteur neuronal pour la protéine de la démence frontotemporale, la progranuline
EP3165537A1 (fr) * 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation de la famille de récepteurs à domaine vps10 pour le traitement de troubles mentaux et du comportement
RU2536232C2 (ru) * 2011-07-01 2014-12-20 Олег Ильич Эпштейн Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
JP6239635B2 (ja) 2012-11-02 2017-11-29 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 血管石灰化の誘導因子であるソルチリン１
IL254887B2 (en) 2015-04-07 2023-11-01 Alector Llc Anti-sortilin antibodies and methods of using them
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
US11396546B2 (en) 2018-07-13 2022-07-26 Alector Llc Anti-Sortilin antibodies and methods of use thereof

Also Published As

Publication number Publication date
CN114478774A (zh) 2022-05-13
TW201702273A (zh) 2017-01-16
RU2018100824A3 (fr) 2020-01-17
JO3710B1 (ar) 2021-01-31
CL2020002468A1 (es) 2021-01-29
TWI760305B (zh) 2022-04-11
GB201512215D0 (en) 2015-08-19
IL256503A (en) 2018-02-28
US10889650B2 (en) 2021-01-12
US20200190188A1 (en) 2020-06-18
ZA201708613B (en) 2021-03-31
US20170267761A1 (en) 2017-09-21
IL256503B (en) 2022-02-01
CO2017012988A2 (es) 2018-05-21
CR20180002A (es) 2018-04-09
RU2018100824A (ru) 2019-08-13
UA125136C2 (uk) 2022-01-19
RU2735639C2 (ru) 2020-11-05
PE20181014A1 (es) 2018-06-26
JP6979397B2 (ja) 2021-12-15
NI201800007A (es) 2018-10-18
DOP2018000014A (es) 2018-04-15
CL2018000092A1 (es) 2018-07-06
AR105335A1 (es) 2017-09-27
MX2018000506A (es) 2018-05-11
US11548950B2 (en) 2023-01-10
US10428147B2 (en) 2019-10-01
CA2989739A1 (fr) 2017-01-19
US20180305455A1 (en) 2018-10-25
EP3322726A1 (fr) 2018-05-23
PH12018500100A1 (en) 2018-07-30
AU2016292980B2 (en) 2022-10-06
TN2017000534A1 (en) 2019-04-12
AU2016292980A1 (en) 2018-01-18
CN114478775A (zh) 2022-05-13
US20230159643A1 (en) 2023-05-25
KR20180030045A (ko) 2018-03-21
ECSP18002725A (es) 2018-03-31
US10479835B2 (en) 2019-11-19
HK1254356A1 (zh) 2019-07-19
SV2018005613A (es) 2018-02-23
US20210269524A1 (en) 2021-09-02
WO2017009327A1 (fr) 2017-01-19
JP2022003058A (ja) 2022-01-11
EA201890038A1 (ru) 2018-06-29
CN107849135A (zh) 2018-03-27
JP2018529635A (ja) 2018-10-11
BR112018000771A2 (pt) 2018-09-25

Similar Documents

Publication Publication Date Title
MA42808A (fr) Anticorps de liaison à l'il-8 et leurs utilisations
MA42440A (fr) Anticorps qui se lient à la sortiline et inhibent la liaison de la progranuline
FR23C1036I2 (fr) Anticorps qui se lient à il-23
FR24C1023I1 (fr) Anticorps thérapeutiques et leurs utilisations
MA46525A (fr) Anticorps anti-lag-3 et compositions
IL287565A (en) Antibodies that bind cd39 and uses thereof
DK3370768T3 (da) Antistoffer som specifikt binder pd-1 og anvendelser deraf
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
MA44659A (fr) Anticorps anti-tim-3 et compositions
IL267113A (en) Antibodies that specifically bind to human IL-15 and their uses
MA49565A (fr) Anticorps agonistes qui lient cd137 humain et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA52273A (fr) Protéines de liaison à un antigène anti-trem2 et leurs utilisations
MA43260A (fr) Liants pd1 et/ou lag3
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
MA44072A (fr) Anticorps se liant spécifiquement à hla-dr et leurs utilisations
MA41313A (fr) Anticorps de liaison de la protéine april modifiés
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
DK3274370T3 (da) Anti-ceacam6-antistoffer og anvendelser deraf
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
MA49846A (fr) Anticorps qui se lient à l'egfr et à cmet
DK3504241T3 (da) Anti-cd3-antistofformuleringer
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations